(S) -Hydroxychloroquine
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


(S) -Hydroxychloroquine
Description :
(S) -Hydroxychloroquine ((S) -HCQ) is the enantiomer of Hydroxychloroquine[1]. Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].CAS Number :
[137433-24-0]Product Name Alternative :
(S) -HCQUNSPSC :
12352005Hazard Statement :
H315-H319-H320Target :
Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)Type :
Reference compoundRelated Pathways :
Anti-infection; Autophagy; Immunology/InflammationApplications :
COVID-19-anti-virusField of Research :
InfectionAssay Protocol :
https://www.medchemexpress.com/s-hydroxychloroquine.htmlSolubility :
10 mM in DMSOSmiles :
CCN(CCO)CCC[C@@H](NC1=CC=NC2=CC(Cl)=CC=C12)CMolecular Formula :
C18H26ClN3OMolecular Weight :
335.87Precautions :
P264-P280-P302+P352-P305+P351+P338-P362References & Citations :
[1]Cardoso CD, et al. Enantioselective analysis of the metabolites of hydroxychloroquine and application to an in vitro metabolic study. J Pharm Biomed Anal. 2005 Apr 1;37 (4) :703-8.|[2]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4 (1) :6.|[3]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85 (3) :429-40.|[4]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . Clin Infect Dis. 2020 Mar 9. pii: ciaa237.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
Plasmodium; TLR7; TLR9

